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Abstract 
In the last two decades, morbidity and mortality of patients with chronic heart failure 
could be further reduced by improved pharmacological and cardiac device therapies. 
However, despite these advances, there is a substantial unmet need for novel 
therapies ideally specifically addressing repair and regeneration of the damaged or 
lost myocardium and its vasculature, given the limited endogenous potential for  
renewal of cardiomyocytes in adults.   
In this respect, cardiac cell-based therapies have gained substantial attention and 
have entered clinical feasibility and safety studies a decade ago.  Different cell-types 
have been used, including bone-marrow-derived mononuclear cells, bone-marrow-
derived mesenchymal stem cells, mobilized CD34+ cells, and more recently cardiac-
derived c-kit+ stem cells and cardiosphere-derived cells.  Some of these studies  
have suggested a potential of cell-based therapies to reduce cardiac scar size and to 
improve cardiac function in patients with ischemic cardiomyopathy.  While first 
clinical trials examining the impact of cardiac cell-based therapy on clinical outcome 
have now been initiated, improved understanding of underlying mechanisms of 
action of cell-based therapies may lead to strategies for optimization of the cardiac 
repair potential of the applied cells.   
In experimental studies direct in vivo reprogramming of cardiac fibroblasts towards  
cardiomyocytes, and microRNA-based promotion of cardiomyocyte proliferation and 
cardiac repair have recently been reported that may represent novel therapeutic 
approaches for cardiac regeneration that would not need cell-administration but 
rather directly stimulate endogenous cardiac regeneration.  
This review will focus mainly on recently completed clinical trials (within the last 2 
years) investigating cardiac cell-based therapies and the current status of 
experimental studies for cardiac cell-based repair and regeneration with a potential 
for later translation into clinical studies in the future.  
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Introduction 
Loss of myocardium rapidly after myocardial infarction and the ongoing death of 
cardiomyocytes thereafter frequently terminates in heart failure, as endogenous 
regeneration pathways cannot replace damaged myocardium and vasculature. 
Unlike in zebrafish,[1, 2]	   division of differentiated cardiomyocytes (CM) is a rare 
event in humans.[3] 
In the last decade, numerous different human cell populations, including bone 
marrow-derived mononuclear cells and CD34+ cells, have been suggested to 
enhance cardiac function and repair in experimental animal models. Several clinical 
studies largely examining feasibility and safety have been performed and have 
yielded mixed results with respect to effects on cardiac function. Cell isolation 
procedures, cell types, number of transplanted cells, and the functional cardiac 
repair capacity of the transplanted cells are likely determinants of their effects on 
cardiac function.[4-6] Here we describe recent experiences of cardiac cell-based 
therapies using different cell populations. 
 
Embryonic stem cells and induced pluripotent stem cells 
Embryonic stem cells (ESCs) share the ability to differentiate in all 3 germ layers 
(pluripotency) and can be infinitely expanded (clonogenicity and self-renewal).[7] 
Therefore, ESCs can be considered as an infinite source to generate the desired 
tissue, particularly as numerous studies have shown differentiation into 
cardiomyocyte-like cells and endothelial cells, and improval of cardiac function after 
transplantation in experimental cardiac injury models.[8-10] However, allogeneic 
transplantation is required, which may cause immunologic reactions after 
transplantation and, as they are obtained from blastocytes, i.e. an early embryonic 
stage, ethical concerns set an additional barrier for wider clinical applications. 
Moreover, because of their ability to expand clonogenically, there is a substantial risk 
of teratogenic potential, at least for undifferentiated ESCs. These aspects limit their 
current use for potential human heart regeneration therapies.  
Man-made dedifferentiated cells, which share similar properties with ESCs are 
termed induced pluripotent stem cells (iPSCs). iPSCs have initially been 
reprogrammed from differentiated fibroblasts in 2006. [11, 12] Since then, 
reprogramming protocols have been refined, thereby raising the efficiency and by 
transfection of recombinant proteins or RNA molecules, such as microRNAs, 
	   4	  
circumvented the initially required transfection procedures with stemness factors (i.e. 
transcription factors highly expressed in ESCs) via retroviruses.[13-15] As they can 
be directed to differentiate towards cardiomyocytes, iPSCs represent a potential 
resource of personalized heart tissue replacement and a valuable tool to further 
understand potential pathways towards cardiac regeneration. Using in vivo imaging, 
we have recently observed viability, tissue distribution and long-term engraftment of 
cellular iPSC-derived grafts in a large animal model of myocardial infarction.[16]   
However, iPSCs share the teratogenic potential with ESCs and recently the immuno-
compatibility of undifferentiated autologous iPSCs has been questioned.[17] 
Moreover as they are genetically modified and require prolonged cultivation times, 
iPSC-derived cells may have a risk for mutations. Hence, the use of iPSCs is 
challenging and not yet feasible for clinical applications. Direct reprogramming of 
cardiac fibroblasts into cardiomyocytes in vivo therefore represents a highly 
interesting perspective.[18, 19] 
 
 
Cardiac-derived progenitor/stem cells  
Amongst somatic progenitor cells, cardiac progenitor cells (CPCs) have been 
postulated to have the highest capacity to promote cardiac regeneration. The 
identification of c-kit+ cells[20] residing in stem cell niches[21] in the murine heart 
that can give rise to the main cellular components of the heart, namely 
cardiomyocytes, endothelial cells and smooth muscle cells have rendered the heart 
as an organ with potential regenerative capacity.  In experimental studies, 
transplantation of c-kit+ cells reconstituted the heart and improved cardiac 
function.[20] Next to c-kit+ cells, other populations as defined by surface markers or 
culture conditions have been suggested as an endogenous source of heart 
regeneration. Isl-1+ cells[22] derive from the second heart field, but can be rarely 
found in postnatal development stages (reviewed in [23]).  Sca-1+ (stem cell antigen-
1) cells[24] are restricted to murine hearts (no orthologue in human), but have also 
been suggested for heart regeneration.[25] Cardiosphere-derived cells (CDCs) are 
cultured from heart biopsies and are named because of their ability to form spheroids 
in cell suspension.[26, 27] CDCs are multicellular clusters containing a mixed cell 
population, which comprise, next to cardiac progenitor cells with c-kit and CD105 
surface marker expression, also other cell types such as mesenchymal stem 
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cells.[26, 28] Experimental data suggest, that heart regeneration of CDCs depends 
on the release of paracrine factors, induction of endogenous regenerative capacity 
and to a lesser extent, on the differentiation into cardiomyocytes and endothelial 
cells in vivo (which has also been controversial).[26, 29, 28, 30] 
All these adult cardiac-derived stem cells are suggested to have self-renewal 
capacities and the ability of multilineage differentiation. Importantly, adult cardiac 
stem cells have the potential to reconstitute damaged myocardium and improve 
cardiac function after heart injury. [28, 25, 29, 20, 31] Moreover, CPCs can be 
obtained by endomyocardial biopsies and sorted according to their surface markers 
and/or expanded in cell culture.  
To this date, 2 published clinical phase I trials have conducted transplantation of 
cardiac-derived cell products in patients with ischemic cardiomyopathy. In the 
randomized SCIPIO-trial, 1x106 c-kit+ cardiac stem cells were delivered intracoronary 
to patients with coronary artery bypass surgery (CABG) and left ventricular ejection 
fraction (LVEF) <40%. The control group received no cell therapy. After 4 months, 
infarct size as assessed by cMRI decreased (however with lacking of control group 
for comparison) and LVEF as assessed by echocardiography significantly increased 
in patients receiving cell therapy. In a subset of patients, cMRI and 
echocardiography measurements were performed after 12 months, which showed an 
even more reduced scar size and improved LVEF. Moreover, although a low number 
of cells was injected, adverse events were comparable with standard care treated 
patients.[32, 33]  
Another, recently published trial, the CArdiosphere-Derived aUtologous stem CElls 
to reverse ventricUlar dySfunction (CADUCEUS) trial,[34] used  intracoronary 
infusion of cardiosphere-derived cells (CDCs) in patients with ventricular dysfunction  
2-3 months after myocardial infarction.  
The CADUCEUS trial[34] suggested a reduction in scar mass and an enhanced 
viable heart mass at 6 and 12 months after transplantation. However, despite these 
beneficial effects, no significant change in LV-function could be observed. 
The pilot data of these 2 clinical trials indicate that intracoronary delivery of heart-
derived cell products is feasible and safe and may improve cardiac function in 
patients with ischemic cardiomyopathy. Although these trials using either selected c-
kit+ cells or CDCs, a mixed cell population, are not directly comparable because of 
different patient population and study designs, both suggest a reduction in scar size, 
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which renders cardiac stem/progenitor cells to an interesting candidate for cell-based 
therapies. However as only few patients were enrolled in the treatment arm (17 
patients in the CADUCEUS trial and 16 patients in the SCIPIO trial) and control 
groups received only standard care, safety and efficacy has to be proven in a 
randomized-blinded, placebo controlled study design. 
Moreover, the finding that CDCs lack MHC II antigens and therefore cause only a 
mild immune reaction after transplantation in the rat infarcted heart[35] initiated the 
ongoing randomized, double-blind, placebo-controlled ALLSTAR (NCT01458405) – 
trial in patients with myocardial infarction and left ventricular dysfunction. With 
allogeneic cell transplantation, biopsies of patients would be needless, cells could be 
injected to a specific time point and circumvent the suggested impairment of adult 
progenitor cells.[36, 37] 
 
 
 
Bone-marrow derived stem cells 
Mechanisms of effects of bone-marrow derived cells on cardiac function: Initially, 
bone-marrow mononuclear cell (BM-MNC)-transplantation was thought to yield its  
effects on cardiac function by transdifferentiation into cardiomyocytes and 
endothelial cells.[38] Later, this concept has been challenged.[39, 40] Experimental 
studies have indicated that direct transdifferentiation of BM-MNCs into 
cardiomyocytes or endothelial cells is (if ever) a very rare event,[39, 40] and could 
not explain the observed effects on cardiac function.  Early studies may therefore 
have rather observed cell fusions than true transdifferentiation of BM-MNCs into 
cardiomyocytes.[40] It is more conceivable that BM-MNCs enhance cardiac repair by 
paracrine effects.[41, 42] Release of growth factors from transplanted BM-MNCs are 
suggested to promote migration of endothelial cells and CPCs and can exert 
cytoprotective effects on resident cardiomyocytes.[43, 44] Particularly, BM-MNCs 
support cardiac angiogenesis and neovascularization in the infarcted heart.[45] 
However, a recent study has also suggested that bone marrow-derived c-kit+ cells 
promote augmentation of cardiomyocyte progenitor activity, which may lead to 
cardiomyocyte formation.[46]  
Recently published (within last 2 years) clinical studies of cardiac cell-based 
therapies using BM-MNCs in patients with myocardial infarction and ischemic 
	   7	  
cardiomyopathy:  As BM-MNCs are an easily accessible cell source (via bone 
marrow aspiration), initial clinical studies have used transplantation of this 
heterogeneous cell population.[47-51] Clinical trials so far showed an excellent 
safety profile and feasibility.  The effects observed in recent clinical studies on LV-
function were more modest as expected, [52-55] however, a meta-analysis of 1765 
participants has suggested a significant improvement of LV-EF, both in short (3.26%) 
and long term (3.91%) follow-up.[56]  
In this regard, clinical trials were initiated by the Cardiovascular Cell Therapy 
Research Network (CCTRN) in patients with significant LV-dysfunction caused by 
ischemic cardiomyopathy and patients with ST-elevation myocardial infarction 
(STEMI).[57, 58] In the FOCUS-CCTRN trial patients with ischemic cardiomyopathy 
were enrolled to receive BM-MNCs by transendocardial administration.[57] In this 
phase II randomized trial, at 6 month, LV end-systolic volume, as assessed by 
echocardiography, did not significantly differ between BM-MNCs administration and 
placebo group. However, exploratory analysis indicated a significant increase in 
LVEF (2.7%) and stroke volume in the treatment group. Although this was the largest 
recent clinical trial conducted in patients with severe LV-dysfunction (LV-EF: 32.4%) 
caused by ischemic cardiomyopathy, the sample size may have been chosen to 
small.  
Clinical data (and some later experimental observations) had suggested that timing 
of BM-MNC delivery after acute myocardial infarction may have an impact on its 
effects on cardiac function.[59, 51] The TIME-trial[58] focused on different time 
points of intracoronary BM-MNC delivery at day 3 and day 7 in patients with ST-
elevation infarction treated with percutaneous primary intervention. However no 
benefit on cMRI detected LV-performance could be observed 6 months after infusion 
of BM-MNCs in either group.[58]  
Moreover, as assessed in the LateTIME[60] and SWISS-AMI[61] trial BM-MNC 
administration 2 to 3 weeks after acute myocardial infarction did not significantly 
affect LV-function.  However, although the SWISS-AMI trial was not powered for this 
endpoint, subgroup analysis indicates a beneficial effect on LV-function after 4 
month when revascularization therapy was performed less than 4.5 hours after 
symptom onset.[61] In addition, these trials may not be powered to detect smaller 
changes in LV function.	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Potential impact of cell isolation procedures and impaired functional capacity of adult 
bone-marrow derived cells: Whereas all clinical trials have supported the safety of 
delivery of BM-MNCs, the lack of a significant beneficial effect after BM-MNC 
delivery on LV-function in some of these studies raises the question of whether this 
patient-derived cell population will be efficient enough for long-term improvement of 
cardiac function.  Importantly, however, the mode of bone-marrow-derived cell 
preparation may play a critical role that likely has been underestimated.	  
For example, certain agents, such as buffer and medium composition during cell 
isolation have been shown to crucially alter cellular function. Heparin, has been 
observed recently to exert detrimental effects on the functionality of BM-MNCs by 
interacting with the CXCR4/SDF-1 axis.[62, 63] The CCTRN–trials have been 
performed using an automated cell-sorting system for the isolation of BM-MNCs.[64, 
65] However, whether these cells are efficient in an experimental myocardial 
infarction model in vivo has not been reported. Therefore, as isolation procedure 
steps may have a crucial influence on cell functionality, the functional properties of 
these cells after automatic separation may be a determinant for the in vivo effects. 	  
In addition, our group could show, that the cardiac repair capacity of angiogenic early 
outgrowth cells (EOCs, also known as circulating angiogenic cells (CACs)) is 
impaired in patients with chronic heart failure caused by ischemic cardiomyopathy as 
compared to healthy subjects in an experimental myocardial infarction model.[36] 
Together with other studies, which show an impairment of migration and angiogenic 
capacity of adult bone marrow-derived mononuclear cells,[66, 67] this might 
contribute to the limited capacity of BM-MNCs in clinical trials to effectively impact on 
cardiac function. In this respect a phase I trial was recently published using 
allogeneic bone marrow derived cells[68] from healthy donors as an off-the-shelf 
product, that may circumvene impairment of autologous cell function in patients with 
cardiovascular disease.  
Bone-marrow-derived and mobilized CD34+ cells for cell-based cardiac therapy: 
Instead of unselected BM-MNCs, distinct cell populations with cardiac repair  
capacity can be isolated from the bone marrow. CD 34+ cells represent a rare 
subpopulation of BM-MNCs with an experimentally high potential of promoting  
angiogenesis and neovascularization in ischemic tissues.[69] In the ACT-34CMI trial, 
intramyocardial administration of low or high dose CD34+ cells was performed in 
patients with ischemic cardiomyopathy and refractory angina pectoris. Of interest, in 
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the low dose CD34+ cell group, a reduction in angina pectoris-frequency and 
improvement in exercise tolerance was observed at 6 and 12 months after 
treatment.[70] This study delineates also an example for trials, which not only take 
functional endpoints in consideration, but focus more on clinical endpoints in patients 
with chronic heart failure, and also questions whether higher numbers of 
intramyocardially applied cells are indeed more efficient.  
In conclusion, it is noteworthy that no adverse events occurred in trials using BM-
MNCs. In addition, a reduction of major adverse cardiovascular events was observed 
in the REPAIR-AMI trial, which maintained for 2 years after acute myocardial 
infarction.[71] This finding is underlined by a recently published meta-analysis.[72] In 
this respect, large scaled phase 3 trials are on the way to identify the effects of BM-
MNCs on clinical outcome and mortality in patients with acute myocardial infarction 
or ischemic cardiomyopathy (BAMI, NCT01569178; REPEAT, NCT01693042). 
 
 
 
Mesenchymal stem cells 
 
Mesenchymal stem cells (MSCs) are a subpopulation of bone-marrow mononuclear 
cells and can be cultured by repeated passaging on plastic surfaces.[73] Typically, 
MSCs are able to differentiate in cartilage, bone or adipose tissue,[73] but also 
differentiation into cardiomyocyte-like cells has been suggested,[74] which has 
rendered them attractive for cardiac regeneration therapies. In addition, MSCs 
release growth factors, indicating also a therapeutically important paracrine function 
and direct cell-cell interactions, which may additionally activate endogenous repair 
mechanisms.[75-79] Moreover, at least initially, MSCs prevent anti-donor T-cell 
responses and create an immunosuppressive milieu, thereby generating an immune 
privileged state.[80] In this regard, experimental studies have demonstrated an 
improved LV-function after allogeneic transplantation of MSCs.[81]  
Both, autologous and allogeneic MSC- administration was tested in clinical trials. 
Chen et al[82] recruited 69 patients after acute myocardial infarction (AMI) for a 
placebo controlled trial using intracoronary delivery of autologous MSCs. 3 months 
after administration, an improved LV-function and decreased left ventricular volumes 
were detected. In addition, a decrease in perfusion defect could be observed, 
indicating reverse remodeling and cardiac regeneration after autologous MSC 
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administration. As an ‘off-the-shelf’ product, MSCs from healthy volunteers were also 
transplanted allogeneically in patients with AMI.[83] Importantly, in this placebo-
controlled trial using intravenous injection, safety outcomes did not differ in the 
treatment arm and furthermore, a decrease in ventricular arrhythmias was 
observed.[83] Notably, LVEF, as assessed with echocardiography, increased 
significantly in patients treated with allogeneic MSCs.[83] 
In the recently published POSEIDON trial,[84] based on pilot data,[85] a head –to-
head comparison between autologous and allogeneic transplantation of MSCs in a 
dose-escalating manner in patients with LV-dysfunction caused by ischemic 
cardiomyopathy was performed. Cell-based treatment associated adverse events 
were low, though a placebo-treated group was missing, and adverse events didn’t 
differ between autologous and allogeneic cell transplantation. 13 month after 
transplantation of MSCs, reverse remodeling, as assessed by LV sphericity index, 
could be observed and a reduction of myocardial infarction size.  However, a 
significant change in LV-EF was not observed. Interestingly, it appeared that low-
dose of MSCs resulted in the greatest reductions in LV-volumes. 
New insights using an intramyocardial delivery approach in patients with ischemic 
cardiomyopathy are under way (TAC-HFT (NCT00768066), PROMETHEUS 
(NCT00587990)) and pilot data from the TAC-HFT study (a placebo-controlled trial) 
suggest potential beneficial effects of MSCs in this patient population.[85] 
 
Priming/Preconditioning of stem cells 
As it was reported that adult progenitor/stem cells are impaired in their functional 
cardiac repair capacity,[37, 66, 36] next to advances in allogeneic cell transplantation 
described above, strategies to enhance functional capacity of autologous 
progenitor/stem cells emerge as promising applications. Preconditioning of 
progenitor cells by ischemic, pharmacological or genetic manipulation to render them 
resistant to the hostile environment in ischemic tissues may enhance their functional 
properties that is currently intensely investigated.[86, 87] 
eNOS-overexpression in EOCs:  Recruitment of angiogenic EOCs (also known as 
CACs) and dysfunction of endothelial cells is critically dependent on endothelial nitric 
oxide synthase (eNOS).[88-90]  In addition, eNOS-expression crucially alters cardiac 
repair capacity of bone marrow-derived progenitor cells in an experimental model of 
ischemic injury.[91] Based on these results, a randomized trial (ENACT-AMI 
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(NTC00936819)) is currently under way to assess potential improvement after 
transplantation of EOCs transfected with human eNOS in patients with acute 
myocardial infarction.[92] 
Growth-factor treatment as a strategy to facilitate and enhance repair capacity of 
progenitor/stem cells: Retention and engraftment of transplanted progenitor/stem 
cells is still an important issue, which is not resolved yet, as only few cells injected 
reside in the designated location.[93] Instead, they are flushed away or die because 
of a hostile milieu in the ischemic heart region. Therefore, in order to equip injected 
cells with a friendlier milieu, Takehara et al[94] transplanted CDCs with a hydrogel 
controlling the release of bFGF (basic fibroblast growth factor), a compound that is 
known to facilitate differentiation, proliferation and survival. CDCs injected with 
hydrogels releasing bFGF showed a superior engraftment and facilitate effects of 
CDCs in pigs with heart failure caused by myocardial infarction.[94] These results led 
to the initiation of the ongoing ALCADIA-trial (NCT00981006) in CABG-patients. 
Another strategy is to pre-treat progenitor/stem cells to enhance their efficacy after 
transplantation. In this regard, Behfar et al pre-treated human MSCs with a growth-
factor cocktail.[95] Thereby, differentiation of human MSCs towards a cardiopoietic 
lineage commitment has been achieved, leading to an improved cardiac function and 
structural benefits in infarcted murine hearts after cell transplantation.[95] These 
cardiopoietic MSCs were subsequently used in a clinical trial with patients with 
ischemic cardiomyopathy. Transplantation of cardiopoietic MSCs was safe and at 6 
months, an increase of LVEF could be observed as compared to the control group 
with standard care.[96]   
microRNA-based pre-treatment to optimize cell-based cardiovascular repair 
capacity:  Key regulators, which are already therapeutically used in patients with 
hepatitis C in a clinical trial (NCT01200420), but have not been translated yet in 
clinical applications for cell-based cardiac therapies, are microRNAs.  These small 
RNAs,[97] which regulate gene expression at the post-transcriptional level mostly by 
degradation of mRNAs, have a highly attractive potential to regenerate damaged 
myocardium in experimental studies after viral delivery.[98] Interestingly, 
dysregulation of microRNAs has been observed in bone marrow-derived cells from 
patients with cardiovascular diseases.[36, 66, 99] Over-expression of the pro-
angiogenic microRNA-126[36] or blocking of microRNA-21 or microRNA-34a[66, 
100] may enhance functional capacity of impaired adult circulating or bone-marrow 
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derived mononuclear cells.  Moreover, several microRNAs have been transfected 
into progenitor cells and improved their biological functions.[101]  
These applications may potentiate and/or restore the functional capacities of applied 
progenitor/stem cells. Thus, preconditioning and priming of cells used for cell-based 
therapies may have not only an important impact on their own functional ability to 
improve cardiac function, but also to enhance the activation of endogenous repair 
mechanisms by paracrine signaling. 
 
 
Conclusions and future directions 
A decade ago, the first in-man-administration of BM-MNCs was performed in a 
patient with myocardial infarction.[93] Since then, thousands of patients have been 
enrolled in clinical trials examining cardiac cell-based therapies. Safety and feasibility 
of bone-marrow-derived cells have so far been excellent, and beneficial effects on 
cardiac function, reverse remodeling and scar size have been observed in some 
studies.  The main focus is still to unravel the ideal approach to regenerate the heart 
in different cardiovascular disease conditions.  
However, reconstitution of the myocardium and sufficient neovascularization after 
cardiac injury may require more than a single injection and/or a combination of 
progenitor/stem cells. In this regard, recently, synergistic effects of simultaneously 
injected MSCs and c-kit+ cells on cardiac function have been observed after 
myocardial infarction in a swine model[102] and a clinical trial with repeated 
injections of BM-MNCs is planned (REPEAT (NCT01693042)).  
iPSCs have a clear potential for cardiac regeneration, but substantial safety and 
practical hurdles are an important limitation.  Direct reprogramming of  cardiac 
fibroblasts into cardiomyocytes, thereby skipping the induction of pluripotent stem 
cells with the associated risks, represents a highly interesting direction of 
research.[18, 19] Recently, systemic application of a microRNA-cocktail[19] or 3 
cardiac transcription factors (Gata4, Mef2c and Tbx5 (GMT))[18] in a murine model 
of myocardial infarction has been reported to directly reprogram cardiac fibroblasts 
into cardiomyocyte-like cells in vivo, leading to an improved cardiac function.[18] 
Recently published clinical trials with cardiac-derived stem cells and the non-
inferiority of allogeneic versus autologous MSCs-transplantation represent 
interesting avenues worth to pursue in the future.  Furthermore, phase III clinical 
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trials are under way to examine the effects  of BM-MNCs administration on all-cause 
mortality in patients with ischemic LV-dysfunction (BAMI, REPEAT).  In addition, ex 
vivo preconditioning to enhance the cardiac repair potential of autologous cells for 
cardiac cell-based therapies may improve their efficacy, in particular in heart failure 
patients.   
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Figure 1 Clinically and experimentally emerging cells for heart regeneration 
therapies	  
 
Allo allogeneic; Auto autologous; BM-MNC bone marrow mononuclear cells; CDCs 
cardiosphere-derived cells; EOCs early outgrowth cells (also known as circulating 
angiogenic cells (CACs) or early endothelial progenitor cells (EPCs); iPSC induced 
pluripotent stem cells; LV-EF left ventricular ejection fraction;  
MSCs mesenchymal stem cells; NYHA new york heart association 
 
 
 
 
Table 1 Selected published and ongoing cell-based clinical studies in patients with 
acute myocardial infarction and/or chronic heart failure   
 
AMI acute myocardial infarction; bFGF basic fibroblast growth factor; BM-MNC bone 
marrow mononuclear cells; CABG coronary artery bypass grafting; 
CDCs cardiosphere-derived cells; DCM dilated cadiomyopathy; eNOS endothelial 
nitric oxide synthase; EPC early endothelial progenitor cells; IC intracoronary 
delivery; ICM ischemic cardiomyopathy; IM intramyocardial; LVEF left ventricular 
ejection fraction; LVESV left ventricular end-systolic volume; MLHFQ minnesota 
living with heart failure questionnaire; MSCs mesenchymal stem cells; MVO2 change 
in maximal oxygen consumption; NYHA new york heart association; PCI 
percutaneous coronary intervention; SAE serious adverse events; STEMI ST-
elevation myocardial infarction	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** This is the first clinical study using c-kit+ cardiac stem cells in patients with 
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** This is the first clinical trial using cardiosphere-derived cells (CDCs) in patients 
with ischemic cardiomyopathy 
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mechanism - namely paracrine signaling - by which adult stem cells exert their 
effects 
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Dimmeler S, Zeiher AM. Intracoronary bone marrow-derived progenitor cells 
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MNCs transplantation in patients with acute myocardial infarction 
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Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, 
Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, 
Kwak M, Moye LA, Simari RD. Effect of the Use and Timing of Bone Marrow 
Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial 
Infarction: The TIME Randomized Trial. Jama. 2012:1-10 
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function: the LateTIME randomized trial. Jama. 2011;306:2110-2119 
Surder D. Intracoronary infusion of BM-MNC early or late after AMI – 4 months 
results of the SWISS-AMI trial. Scientific Sessions of the AHA – Late braking 
trials 2012 
* Ref 58, 60 and 61 are all well-designed clinical trials that investigated BM-MNCs 
administration at different time points in patients with acute myocardial infarction and 
left ventricular dysfunction  
 
Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, 
Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, 
Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA. Intramyocardial, 
autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109:428-
436 
* This clinical study demonstrates a reduction of angina pectoris frequency in 
patients with Canadian Cardiovascular Society (CCS) class III–IV refractory angina 
after intramyocardial delivery of CD34+ cells and emphasizes that relief of symptoms 
may emerge as an important target of cell-based therapies 
 
Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult 
bone marrow cell therapy improves survival and induces long-term 
improvement in cardiac parameters: a systematic review and meta-analysis. 
Circulation. 2012;126:551-568 
* This up-to-date meta-analysis highlights beneficial short- and long-term effects 
after BM-MNCs administration in 2625 patients with ischemic heart disease 
 
Hare JM, Fishman JE, Gerstenblith G, Difede Velazquez DL, Zambrano JP, Suncion 
VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, 
Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, 
Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW. 
Comparison of Allogeneic vs Autologous Bone Marrow-Derived Mesenchymal 
Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic 
Cardiomyopathy: The POSEIDON Randomized Trial. Jama. 2012:1-11 
** This clinical trial investigated transendocardial delivery of allogeneic and 
autologous MSCs head-to-head in patients with ischemic cardiomyopathy (ICM) 
 
Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway SJ, Fu JD, 
Srivastava D. In vivo reprogramming of murine cardiac fibroblasts into 
induced cardiomyocytes. Nature. 2012;485:593-598 
* This experimental study shows that systemic delivery of cardiac transcription 
factors can directly reprogram resident cardiac fibroblasts into cardiomyocyte–like 
cells 
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Selected published clinical trials in 2011/2012 using cell-based therapies for cardiac disease   
Study Phase n (treated/ control) Cell type Condition 
Donor type 
Groups 
Modification 
Delivery Placebo Primary endpoints Results 
ClinicalTrial 
Identifier Citation 
CPCs                       
SCIPIO I 16/7 c-kit+ post-CABG   IC 
yes 
(standard 
care) 
SAE SAE -, LVEF, infarct size NCT00474461 32 
              
CADUCEUS I 17/8 CDC ICM   IC 
yes 
(standard 
care) 
SAE SAE -, scar mass, LVEF - NCT00893360 34 
              
              
BM-MNCs             
FOCUS II 61/31 BM-MNC ICM   IM yes (Placebo injection) 
LVESV, MVO2, 
reversible defect 
LVESV -, MVO2 -, 
reversible defect - NCT00824005 57 
              
TIME II  BM-MNC STEMI       NCT00684021 58 
   41/22   3 days after PCI IC 
yes (Placebo 
injection) 
LVEF, regional 
left ventricular 
function 
LVEF -, regional left 
ventricular function -     
   34/15   7 days after PCI IC 
yes (Placebo 
injection) 
LVEF, regional 
left ventricular 
function 
LVEF -, regional left 
ventricular function -     
              
LateTIME II 55/26 BM-MNC AMI 2 to 3 weeks after PCI IC 
yes (Placebo 
injection) 
LVEF, regional 
left ventricular 
function 
LVEF -, regional left 
ventricular function -, LV 
volumes -, infarct size - 
NCT00684060 60 
              
              
SWISS-AMI II 107/60 BM-MNC STEMI    
yes 
(standard 
care) 
  NCT00355186 61 
       5-7 days after PCI IC  LVEF LVEF -, infarct size -,     
       3-4 weeks after PCI IC  LVEF LVEF -, infarct size -,     
              
ACT34-CMI II 109/53 CD34 
ICM 
(refractory 
angina) 
 IM yes (Placebo injection) 
angina pectoris 
frequency  
angina frequency, 
execise tolerance NCT00300053 70 
                       
              
MSCs             
POSEIDON I/II 15/15 (allo/auto) MSC ICM 
allogeneic and 
autologous IM no SAEs 
SAE -, auto/allo: infarct 
size, LVEF -; 
allogeneic: 6-min walk 
test, MLHFQ 
NCT01087996 84 
C-Cure II/III 21/24 MSC ICM 
Pre-treatment 
with growth 
factors 
IM 
yes 
(standard 
care) 
LVEF LVEF NCT00810238 96 
            
            
Selected ongoing clinical trials using cell-based therapies for cardiac disease   
CPCs                       
ALLSTAR I/II  CDC ICM allogeneic IC yes (Placebo injection) Infarct size, SAEs  NCT01458405   
              
ALCADIA I  CDC CABG bFGF gelatin sheet IM no SAEs  NCT00981006   
              
              
BM-MNCs             
REPEAT II/III  BM-MNC ICM single/repeated delivery IC no Mortality  NCT01693042   
              
BAMI III  BM-MNC  STEMI   IC 
yes 
(standard 
care) 
All cause death  NCT01569178   
              
REGEN-AMI II/III  BM-MNC STEMI Delivery within hours after PCI IC 
yes (Placebo 
injection) LVEF  NCT00765453   
              
IMPACT-CABG II  CD133+ CABG   IM yes (Placebo injection) 
SAEs, major 
arrhythmia  NCT01033617   
              
PERFECT III  CD133+ CABG   IM yes (Placebo injection) LVEF  NCT00950274   
              
PreSERVE-AMI II  CD34+ STEMI   IC 
yes 
(standard 
care) 
SAE, myocardial 
perfusion  NCT01495364   
              
ENACT-AMI II  EPC STEMI eNOS over-expression IC 
yes (Placebo 
injection) LVEF  NCT00936819   
              
              
MSCs             
PROMETHEUS I/II  MSC post-CABG    IM yes (Placebo injection) SAEs  NCT00587990   
              
TAC-HFT I/II  MSC or BMC ICM    IM 
yes (Placebo 
injection) SAEs  NCT00768066   
               
POSEIDON DCM I/II   MSC DCM allogeneic and autologous IM no SAEs   NCT01392625   
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
               	  
